We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Provisional assignment of new diseases of uncertain etiologyInflammatory polyarthropathiesSystemic connective tissue disorders
This information is provided directly by researchers and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information.
People living with immune-mediated inflammatory diseases (IMID) raise specific concerns due to their potentially increased risk of infections, related both to the disease itself and its treatment. Accordingly, patients aware of their high-risk condition could react differently from the general population, when considering their fears and beliefs facing the pandemic.
Few small retrospective studies have been published about COVID-19 among IMID patients. However, data concerning prevalence and clinical course of COVID-19 among IMID patients are lacking. By the time when the pandemic peak is about to be reached in some European countries, while only starting in others, it would be very helpful to know the prevalence and prognosis of IMID patients infected with COVID-19.
To date, no treatment is robustly validated for COVID-19. These groups of patients are generally on specific treatments depending on the severity of their condition. There is a substantial risk of untimely treatment discontinuation by patients themselves as many of them question their physicians on immunomodulating agents (substance that stimulates or suppresses the immune system) risks in the outbreak context, asking to reduce or even stop them. This interruption could then lead to a disease flare. IMID's flare in this setting also needs to be assessed, since it can range from small impact on daily activities to more severe or life-threatening consequences, depending on the underlying disease.
We thus aim to investigate prevalence and seroconversion of COVID-19 in IMID. To assess the patient’s psychological, clinical and therapeutic impact among distinct IMID through different European countries will provide a unique and useful information that can be used to build robust public health policies. Some of the diseases we will be considering in this study: Sjögren’s syndrome, systemic lupus erythematosus, rheumatoid arthritis, axial spondyloarthritis and giant cell arteritis.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cross-sectional;
You can take part if:
You may not be able to take part if:
- Patients who refuse to participate; - Patients who don’t speak or read the local language; - Patients unable to perform a routine blood collection during the study period.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by LONDON NORTH WEST UNIVERSITY HEALTHCARE NHS TRUST and funded by GROUP ETUD RECHER PATHOLOG APPARLOCOMOT (GERPAL) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 46279
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
